Company profile for SynAct Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The company’s technology is focused on development of agonist to target the melanocortin system . The melanocortin system is activated in inflammatory conditions and contributes with anti- inflammatory effects, and stimulates important components of the healing process and for recovery to normal tissue function. SynAct’s drug candidate AP1189 is first in class compound reaching the melanocortin system for once daily oral ...
The company’s technology is focused on development of agonist to target the melanocortin system . The melanocortin system is activated in inflammatory conditions and contributes with anti- inflammatory effects, and stimulates important components of the healing process and for recovery to normal tissue function. SynAct’s drug candidate AP1189 is first in class compound reaching the melanocortin system for once daily oral dosing that stimulates the relevant receptors in the melanocortin system, and thereby avoiding unwanted side effects.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Sweden
Address
Address
c/o Medicon Village AB, Sheelevägen 2,SE-223 81 Lund
Telephone
Telephone
+45 28 44 75 67
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://synactpharma.com/en/approval-of-amended-study-protocol-for-the-phase-2a-study-in-imn/

PRESS RELEASE
16 Sep 2022

https://news.cision.com/synact/r/synact-announces-outcome-of-rights-issue,c3552845

CISION
25 Apr 2022

https://www.prnewswire.com/news-releases/synact-pharma-announces-positive-interim-phase-2-data-of-ap1189-in-rheumatoid-arthritis-301168425.html

PRNEWSWIRE
09 Nov 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty